Healthcare · Biotechnology
Price
$38.86
Market Cap
$4.5B
Employees
59
Beta
0.66
Avg Volume
2,436,298
CEO
Brian Lian
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Runs with full report
Price Overview
Last updated: Jul 12, 2026 3:33pm (just now)
Current data · timestamped when a report runs
$38.86
Change · Jul 12
-2.28 (-5.54%)
Day Range
$38.20 – $41.14
52-Week Range
$22.96 – $43.15
50-Day MA
$32.58
200-Day MA
$33.31
Volume
2,158,829.00
Analyst Price Targets
Low
$83.00
Consensus
$93.60
High
$101.00
(25 analysts)
Share Structure
Outstanding
116,105,643.00
Float
112,858,863.00
Free Float
97.2%
High free float
— 97.2% of shares trade freely, ~2.8% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-12.18
Stock Price: $38.86
EPS (Diluted): -3.19
EPS (Diluted): -3.19
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
6.20
Stock Price: $38.86
Total Equity: $639.06M
Shares: 112,667,000
Total Equity: $639.06M
Shares: 112,667,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-9.31
Market Cap: $4.51B
Total Debt: $0.00
Cash: $165.81M
EBITDA: -$359.15M
Total Debt: $0.00
Cash: $165.81M
EBITDA: -$359.15M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$3.8B
Market Cap: $4.51B
Total Debt: $0.00
Cash: $165.81M
Total Debt: $0.00
Cash: $165.81M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $38.86
Revenue: $0.00
Shares: 112,667,000
Revenue: $0.00
Shares: 112,667,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$431,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$393.34M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$359.64M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-71.3%
Net Income: -$359.64M
Total Equity: $639.06M
Total Equity: $639.06M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-100.0%
Operating Income: -$393.34M
Tax Rate: 0.0%
Equity: $639.06M
Total Debt: $0.00
Cash: $165.81M
Tax Rate: 0.0%
Equity: $639.06M
Total Debt: $0.00
Cash: $165.81M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
9.33
Current Assets: $715.60M
Current Liabilities: $76.67M
Current Liabilities: $76.67M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $639.06M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $639.06M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 112,667,000
Shares: 112,667,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$5.67
Total Equity: $639.06M
Shares: 112,667,000
Shares: 112,667,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-2.47
Operating CF: -$278.69M
CapEx: $0.00
Shares: 112,667,000
CapEx: $0.00
Shares: 112,667,000
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $38.86
Stock Price: $38.86
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$359.64M
Net Income: -$359.64M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VKTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 12, 2026 3:33pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $431,000 |
| Gross Profit | $0 | $0 | $0 | $0 | $-431,000 |
| Operating Expenses | $55.7M | $70.4M | $100.8M | $150.9M | $393.3M |
| Operating Income | -$55.7M | -$70.4M | -$100.8M | -$150.9M | -$393.3M |
| Net Income | -$55.0M | -$68.9M | -$85.9M | -$110.0M | -$359.6M |
| EBITDA | -$54.7M | -$68.5M | -$85.5M | -$109.5M | -$359.2M |
| EPS | $-0.70 | $-0.88 | $-0.91 | $-1.01 | $-3.19 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 12, 2026 3:33pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M |
| Total Current Assets | $210.5M | $167.0M | $367.2M | $907.2M | $715.6M |
| Total Assets | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M |
| Current Liabilities | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M |
| Total Equity | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M |
| Retained Earnings | -$223.2M | -$292.0M | -$377.9M | -$487.9M | -$847.5M |
Cash Flow (Annual)
Last updated: Jul 12, 2026 3:33pm (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$278.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$6.8M | $0 | $0 | $0 |
| Net Change in Cash | -$2.7M | $10.3M | $18.9M | -$28.8M | $139.1M |
Analyst Estimates (Annual)
Last updated: Jul 12, 2026 3:33pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$7.3M $7.3M – $7.3M
|
$161.5M $161.5M – $161.5M
|
$474.5M $474.5M – $474.5M
|
$1.2B $1.2B – $1.2B
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$587.4M -$770.5M – -$266.8M
|
-$499.2M -$761.9M – -$29.8M
|
-$195.4M -$195.4M – -$195.4M
|
$243.8M $243.8M – $243.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 12, 2026 3:33pm (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -26.4% | -43.3% | -49.7% | -160.6% |
| Net Income Growth | -25.2% | -24.7% | -28.0% | -227.1% |
| EBITDA Growth | -25.3% | -24.8% | -28.1% | -227.9% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-01 | Chen Hubert C | A-Award | 190,000.00 | $31.27 | $5.9M |
| 2026-06-01 | Chen Hubert C | 0.00 | $0.00 | $0 | |
| 2026-03-10 | Aubuchon Neil William | P-Purchase | 4,475.00 | $33.50 | $149,913 |
| 2026-01-12 | Aubuchon Neil William | A-Award | 180,000.00 | $31.76 | $5.7M |
| 2026-01-12 | Aubuchon Neil William | 0.00 | $0.00 | $0 | |
| 2026-01-02 | ZANTE GREG | A-Award | 32,049.00 | $0.00 | $0 |
| 2026-01-05 | ZANTE GREG | S-Sale | 31,961.00 | $32.30 | $1.0M |
| 2026-01-02 | ZANTE GREG | A-Award | 41,000.00 | $0.00 | $0 |
| 2026-01-05 | ZANTE GREG | S-Sale | 13,900.00 | $33.38 | $464,021 |
| 2026-01-05 | ZANTE GREG | S-Sale | 10,300.00 | $34.24 | $352,635 |
| 2026-01-05 | ZANTE GREG | S-Sale | 1,500.00 | $32.09 | $48,133 |
| 2026-01-02 | ZANTE GREG | A-Award | 91,000.00 | $35.42 | $3.2M |
| 2026-01-02 | Mancini Marianna | A-Award | 32,049.00 | $0.00 | $0 |
| 2026-01-05 | Mancini Marianna | S-Sale | 31,961.00 | $32.29 | $1.0M |
| 2026-01-02 | Mancini Marianna | A-Award | 41,000.00 | $0.00 | $0 |
| 2026-01-05 | Mancini Marianna | S-Sale | 13,600.00 | $33.37 | $453,876 |
| 2026-01-05 | Mancini Marianna | S-Sale | 10,500.00 | $34.22 | $359,303 |
| 2026-01-05 | Mancini Marianna | S-Sale | 1,600.00 | $35.07 | $56,117 |
| 2026-01-02 | Mancini Marianna | A-Award | 91,000.00 | $35.42 | $3.2M |
| 2026-01-02 | Lian Brian | A-Award | 224,080.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for VKTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for VKTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.417 · 876ff812 · 2026-07-12 14:48:47